M. Michelle Berrey

M. Michelle Berrey, M.D., M.P.H., serves as the President of Research & Development and Chief Medical Officer. Michelle was most recently President and Chief Executive Officer at Chimerix from 2012 to 2019 where the focus was on viral infections in immunocompromised hosts. Prior to Chimerix, she served as Chief Medical Officer at Pharmasset where she played a critical role in the development of Sovaldi® (sofosbuvir) for hepatitis C. Michelle began her career in drug development at GlaxoSmithKline. She served in multiple roles at GW/GSK, eventually serving as Vice President, Viral Diseases, Clinical Pharmacology & Discovery Medicine. During her time at GSK, she was responsible for the early development of compounds for the treatment of HIV, hepatitis viruses, and hepatic fibrosis. Dr. Berrey received her M.D. from the Medical College of Georgia/Augusta University, and a Master of Public Health from Emory University. She completed her internal medicine residency at UNC-Chapel Hill and a fellowship in Infectious Diseases at UW in Seattle, where her research focused on the transmission of HIV, early establishment of the viral reservoir, and the potential for early antiviral therapy during acute infection.